Viatris launches review, plans share buybacks. CEO outlines strategy for cost structure and remediation efforts.

A U.S. appeals court on Monday gave Viatris' Mylan Pharmaceuticals another chance to prove that its proposed generic of Johnson & Johnson unit Actelion's cardiovascular drug Veletri would not ...

Viatris Inc (Symbol: VTRS) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Our Top 5 Analyst Questions Viatris’s Q1 Earnings Call Chris Schott (JPMorgan) asked about the sales ramp and infrastructure for fast-acting meloxicam and the company’s ability to mitigate ...

The Turner Station resident's family filed its third lawsuit related to the HeLa cell line, accusing Novartis and Viatris of unjust enrichment.

In trading on Monday, shares of Viatris Inc (Symbol: VTRS) crossed above their 200 day moving average of $10.86, changing hands as high as $11.43 per share. Viatris Inc shares are currently ...

Shareholder Suit Alleges Viatris Failed to Inform Market of Plans to Sell Biosimilars Portfolio This suit was surfaced by Law.com Radar. Read the complaint here. September 05, 2023 at 11:15 AM 1 ...

Viatris Inc. Robert J. Coury Global Center 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Phone1 724 514-1800 IndustryPharmaceuticals SectorHealth Care/Life Sciences Fiscal Year-end12/2025 ...

Goldman Sachs on Friday reviewed the generic drug industry, initiating the coverage of Teva Pharmaceutical (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX) with Buy ratings and Viatris (NASDAQ ...